A highrisk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00550232
Genomic complexity of multiple myeloma and its clinical implications, Nat Rev Clin Oncol, vol.14, issue.2, pp.100-113, 2017. ,
DOI : 10.1038/nrclinonc.2016.122
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood, vol.127, issue.24, pp.2955-62, 2016. ,
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death, J Clin Oncol, vol.32, issue.20, pp.2173-80, 2014. ,
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?, Crit Rev Oncol Hematol, vol.112, pp.153-70, 2017. ,
PRIMA1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, issue.10, pp.1626-1662, 2014. ,
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, issue.4, pp.285-293, 2015. ,
The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006. ,
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.72, issue.17, pp.4562-73, 2012. ,
ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3911, 2011. ,
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.28, issue.1, pp.210-212, 2014. ,
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other, Leuk Lymphoma, vol.55, issue.9, pp.2165-73, 2014. ,
RITA (reactivating p53 and inducing tumor apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway, BMC Cancer, vol.14, p.437, 2014. ,
Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma, Oncotarget, vol.6, issue.29, pp.26922-26956, 2015. ,
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes, Nat Commun, vol.6, p.5901, 2015. ,
ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization, Mol Biosyst, vol.12, issue.2, pp.477-486, 2016. ,
DOI : 10.1039/c5mb00663e
clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, vol.16, issue.5, pp.284-291, 2012. ,
DOI : 10.1089/omi.2011.0118
URL : http://europepmc.org/articles/pmc3339379?pdf=render
Maftools: efficient and comprehensive analysis of somatic variants in cancer, Genome Res, vol.28, issue.11, pp.1747-56, 2018. ,
A highperformance computing toolset for relatedness and principal component analysis of SNP data, Bioinformatics, vol.28, issue.24, pp.3326-3334, 2012. ,
Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma, J Clin Oncol, vol.33, issue.33, pp.3911-3931, 2015. ,
Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, issue.7339, pp.467-72, 2011. ,
DOI : 10.1038/nature09837
URL : https://www.nature.com/articles/nature09837.pdf
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, issue.1, pp.91-101, 2014. ,
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker, Blood Cancer J, vol.7, issue.2, p.535, 2017. ,
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma, Blood, vol.128, issue.13, pp.1735-1779, 2016. ,
DOI : 10.1182/blood-2016-06-723007
URL : http://www.bloodjournal.org/content/128/13/1735.full.pdf
Compendium of FAM46C gene mutations in plasma cell dyscrasias, Br J Haematol, vol.174, issue.4, pp.642-647, 2016. ,
Wholeexome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Oncotarget, vol.6, pp.17543-58, 2015. ,
DOI : 10.18632/oncotarget.4028
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=4028&path%5B%5D=10008
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, vol.6, issue.27, pp.24205-24222, 2015. ,
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature, Oncotarget, vol.7, issue.16, pp.21353-61, 2016. ,
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, Leuk Lymphoma, vol.0, issue.0, pp.1-6, 2018. ,
Clonal evolution in newly diagnosed multiple myeloma patients: a followup study from the Mmrf Commpass Genomics Project, Blood, vol.130, issue.1, p.325, 2017. ,
Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance, Blood, vol.130, issue.1, p.266, 2017. ,
The spectrum and clinical impact of epigenetic modifier mutations in myeloma, Clin Cancer Res, vol.22, issue.23, pp.5783-94, 2016. ,
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell, Blood Rev, vol.31, issue.4, pp.251-59, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01493742
Discovery of a potent and selective BCL-XL inhibitor with in vivo activity, ACS Med Chem Lett, vol.5, issue.10, pp.1088-93, 2014. ,
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death Dis, vol.6, p.1590, 2015. ,
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, vol.11, issue.5, p.77, 2009. ,
Frequent engagement of the classical and alternative NF-?B pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007. ,
DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells, Mol Pharmacol, vol.56, issue.3, pp.478-84, 1999. ,
RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma, Br J Haematol, vol.177, issue.1, pp.80-94, 2017. ,
A DNA targetenrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma, Blood Cancer J, vol.6, issue.9, p.467, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01382540
False human hematopoietic cell lines: cross-contaminations and misinterpretations, Leukemia, vol.13, issue.10, pp.1601-1608, 1999. ,
DOI : 10.1038/sj.leu.2401510
URL : http://www.nature.com/articles/2401510.pdf
False and mycoplasmacontaminated leukemia-lymphoma cell lines: time for a reappraisal, Int J Cancer, vol.140, issue.5, pp.1209-214, 2017. ,
Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought, Cancer Cell, vol.34, issue.1, pp.9-20, 2018. ,
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma, Leuk Lymphoma, vol.56, issue.12, pp.3320-3328, 2015. ,
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma, Blood, vol.119, issue.20, pp.4597-607, 2012. ,
Cyclin-dependent kinase 4/6 inhibitors in hormone receptorpositive early breast cancer: preliminary results and ongoing studies, Breast Cancer, vol.25, issue.5, pp.506-522, 2018. ,
, Pellat-Deceunynck C. p53 regulates CD46 expression and Measles virus infection in myeloma cells. Blood Advances
The non-canonical poly(A) polymerase FAM46C acts as an oncosuppressor in multiple myeloma, Nat Commun, vol.8, issue.1, p.619, 2017. ,
A diverse range of gene products are effectors of the type I interferon antiviral response, Nature, vol.472, issue.7344, pp.481-486, 2011. ,
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma, Leukemia, vol.31, issue.12, pp.2791-2799, 2017. ,
Integrative analysis of the genomic landscape underlying multiple myeloma at diagnosis: an Mmrf Commpass Analysis, Blood, vol.130, issue.1, p.326, 2017. ,
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, issue.7626, pp.477-82, 2016. ,